Pichardo, Merycarla
Rijo, Edwin
Espino, Gustavo
Lay, Ramon Rodriguez
Estrella, Rafael
Gonzalez, Cristian
Fernandez, Marlin
Soriano, David
Peralta, Ingris M.
Kaplan, Steven A. http://orcid.org/0000-0003-2558-7306
Clinical trials referenced in this document:
Documents that mention this clinical trial
Durable benefit after treatment of obstructive benign prostatic hyperplasia with a novel drug-device combination product: 2-year outcomes from the EVEREST-I study
https://doi.org/10.1007/s00345-023-04473-1
Funding for this research was provided by:
Urotronic, Inc.
Article History
Received: 2 March 2023
Accepted: 31 May 2023
First Online: 24 June 2023
Declarations
:
: SAK is the principal investigator of multiple Urotronic sponsored studies. The other authors declare no conflicts.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Ethics committee approval was obtained before conducting study activities. Written informed consent was obtained from all individual participants included in the study.